Under a tenth of people that would benefit from obesity jabs like Wegovy are able to get them, states the WHO as it issues its initial guidance on the medications.
Considering over a billion individuals worldwide currently obese, it is advocating for broader and more equitable access to this class of drugs.
Based on estimates, in excess of 2,000,000,000 will be living with obesity by 2030 if no action is taken.
"Our new guidelines recognises that excess weight is a long-term condition that can be treated with comprehensive and lifelong treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and logistical bottlenecks are significant barriers to widespread access to the treatments that can help people shift considerable body mass, explains the agency.
Skinny Jab Supply Crisis
Even in the present best projected case, the manufacturing of these medications might only reach around 100 million people – less than 10% of eligible patients, as stated by the WHO.
The recommendation calls on governments and firms to widen access, via strategies like voluntary licensing.
The intellectual property rights on semaglutide – the core component of the drug Wegovy – is scheduled to end in a number of countries in 2026.
How Weight-Loss Injections Work
The injections imitate a body's own hormone to reduce digestion speed, suppress the appetite and enhance feelings of fullness so users eat less.
People usually begin shedding pounds in the initial weeks of commencing the regular doses.
Research points to people may see weight return a year later of stopping the treatment, when their usual food cravings come back.
To be carrying excess weight increases your risk for contracting medical conditions, like type 2 diabetes, cardiovascular issues, stroke, and some cancers.
Excess weight affects people in countries worldwide and was responsible for 3.7 million deaths worldwide in 2024, as per the health agency.
